Alkem's Strategic Move to Acquire JB Pharma Amid Torrent's Withdrawal

Thursday, 12 September 2024, 20:25

Alkem seeks to acquire JB Pharma amidst recent market shifts. Torrent Pharmaceuticals has stepped back from negotiations, citing valuation disparities. Alkem's ongoing talks reflect its robust position in the pharmaceutical market.
Moneycontrol
Alkem's Strategic Move to Acquire JB Pharma Amid Torrent's Withdrawal

Alkem's Ambitious Plans for Acquisition

India’s fifth largest drugmaker Alkem Laboratories has joined the competition to acquire JB Chemicals and Pharmaceuticals. This move comes as private equity firm KKR looks to capitalize on market opportunities, as reported by The Economic Times on September 13.

Torrent Exits Acquisition Discussions

Recently, Torrent Pharmaceuticals, which was considered a leading contender for the $3 billion acquisition of JB Pharma, has withdrawn from the discussions due to valuation conflicts.

Investment and Stake Sale Talks

On September 12, it was reported that Alkem’s promoters, the Singh family, are exploring options to sell a significant stake in the company to private equity firms.

  • Nomura has been engaged to identify potential buyers for Alkem's controlling interest.
  • Alkem is recognized for its successful portfolio in anti-infectives and pain management.
  • The company also holds a growing array of treatments for chronic conditions.

In conclusion, the situation surrounding Alkem’s acquisition strategy reflects the intense dynamics within the pharmaceutical industry.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe